Jeffrey Wiezorek, SVP Clinical Development at Kite Pharma, Inc. (KITE), sold 1,388 shares at $44.47 ($62K) on 2016-02-16, disclosed to the SEC on 2016-02-18.
Open-market sale of $62k KITE by SVP Clinical Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| KITE | SELL | 2017-07-06 | $1.0M | — | Filing → |
| KITE | SELL | 2017-03-02 | $1.4M | — | Filing → |
| KITE | SELL | 2017-02-06 | $77K | — | Filing → |